Mesonephric Adenocarcinoma and Mesonephric-like Adenocarcinoma of the Urinary Tract. 

 -  2023 
<br/><br/> Given the association of mesonephric adenocarcinoma (MA) of the uterine cervix with florid mesonephric hyperplasia, one would expect MAs to rarely arise in other anatomical locations that harbor mesonephric remnants. In contrast, mesonephric-like adenocarcinoma (MLA) is thought to arise from Mullerian origin without an association with mesonephric remnants. The current case series characterizes 4 cases of MA arising in the urinary bladder (1 woman and 3 men), 1 case of MA in the perirenal region (woman), and 1 case of MLA in the ureter (woman). All cases displayed morphologic features similar to MA of the uterine cervix and MLA of the ovary and endometrium, characterized by predominant tubular and focal glandular/ductal architecture. Mesonephric remnants in the bladder wall were closely associated with adjacent MA in cases 1 and 4. MLA in case 6 was associated with mesonephric-like proliferations and endometriosis. All cases (6/6) were diffusely positive for Pax8, and all displayed a luminal pattern of CD10 staining, except case 4 for which CD10 immunostain was not available for review. Gata3 was either focally positive (cases 1, 2, and 6), negative (case 3), or diffusely positive (case 5). TTF-1 was diffusely expressed in cases 1 and 3 and negative in cases 2, 5, and 6. Although a KRAS G12C somatic mutation was detected in case 6, hotspot mutations in KRAS, NRAS, and PIK3CA were not present in other tested cases. Our study demonstrates that MAs and MLAs of the urinary tract share similar histopathogenesis, morphology, and immunophenotype to their counterparts in the female genital tract. We propose that, in the urinary tract, MA might be classified as a distinctive tumor that arises from mesonephric remnants or presumed Wolffian origin if they are not related to Mullerian-type precursors. The tumor displaying similar morphology and immunoprofile to MA but associated with Mullerian-type precursors should be classified as MLA. Copyright © 2022 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>0893-3952 
<br/><br/><label>Standard No.: </label>10.1016/j.modpat.2022.100031 [doi] S0893-3952(22)00031-X [pii] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Adenocarcinoma<br/>*Mesonephroma<br/>*Urinary Tract<br/>*Uterine Cervical Neoplasms<br/>Adenocarcinoma/ge [Genetics]<br/>Adenocarcinoma/pa [Pathology]<br/>Female<br/>Humans<br/>Male<br/>Mesonephroma/ge [Genetics]<br/>Mesonephroma/pa [Pathology]<br/>Proto-Oncogene Proteins p21(ras)<br/>Urinary Tract/pa [Pathology]
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Pathology and Laboratory Medicine
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Research Support, Non-U.S. Gov't